Citigroup’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-160
Closed 8216
2015
Q4
$0 Hold
160
﹤0.01% 8291
2015
Q3
$0 Hold
160
﹤0.01% 8289
2015
Q2
$0 Hold
160
﹤0.01% 8134
2015
Q1
$0 Hold
160
﹤0.01% 7811
2014
Q4
$1K Hold
160
﹤0.01% 7063
2014
Q3
$1K Sell
160
-24,300
-99% -$70.8K ﹤0.01% 7023
2014
Q2
$63K Buy
24,460
+100
+0.4% +$277 ﹤0.01% 5013
2014
Q1
$68K Sell
24,360
-400
-2% -$1.21K ﹤0.01% 5293
2013
Q4
$67K Buy
24,760
+400
+2% +$1.12K ﹤0.01% 5552
2013
Q3
$195K Sell
24,360
-800
-3% -$6.16K ﹤0.01% 4175
2013
Q2
$184K Buy
+25,160
New +$182K ﹤0.01% 4346

Other funds holding CELGZ

Citigroup's CELGZ Position: Q1 2016 in Review

Citigroup sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q1 2016, closing a stake of 160 shares.

Citigroup first reported a position in CELGZ in Q2 2013 and held it in 11 quarters. The position peaked at $195K in Q3 2013. 25 funds tracked by Wall St. Rank hold CELGZ as of Q1 2016.

  • Citigroup reported no remaining Celgene Corporation Contingent Value Rights position as of Q1 2016 after selling out during the quarter.
  • Citigroup sold 160 Celgene Corporation Contingent Value Rights shares in Q1 2016.
  • Citigroup first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 11 quarters.
  • Citigroup's Celgene Corporation Contingent Value Rights position peaked at $195K in Q3 2013.
  • 25 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q1 2016.

Based on Citigroup's 13F filing for Q1 2016, filed 13 May 2016.